JUBLPHARMA Stock Overview
Operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Jubilant Pharmova Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,105.20 |
| 52 Week High | ₹1,309.90 |
| 52 Week Low | ₹532.15 |
| Beta | 1.58 |
| 1 Month Change | -10.46% |
| 3 Month Change | -5.56% |
| 1 Year Change | 91.23% |
| 3 Year Change | 89.17% |
| 5 Year Change | 107.72% |
| Change since IPO | 1,208.39% |
Recent News & Updates
Insufficient Growth At Jubilant Pharmova Limited (NSE:JUBLPHARMA) Hampers Share Price
Dec 21
Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Nov 15A Look At The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Oct 27Recent updates
Insufficient Growth At Jubilant Pharmova Limited (NSE:JUBLPHARMA) Hampers Share Price
Dec 21Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Nov 15A Look At The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Oct 27Jubilant Pharmova Limited (NSE:JUBLPHARMA) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Aug 24Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Jul 13Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Mar 14Jubilant Pharmova Limited (NSE:JUBLPHARMA) Shares Fly 27% But Investors Aren't Buying For Growth
Dec 23These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Dec 02These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Jul 26Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
May 11Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Dec 10Jubilant Pharmova (NSE:JUBLPHARMA) Has Announced A Dividend Of ₹5.00
Aug 01Does Jubilant Pharmova (NSE:JUBLPHARMA) Have A Healthy Balance Sheet?
Jun 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Mar 22Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Feb 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Dec 20Here's Why It's Unlikely That Jubilant Pharmova Limited's (NSE:JUBLPHARMA) CEO Will See A Pay Rise This Year
Sep 15Here's Why Jubilant Pharmova (NSE:JUBLPHARMA) Can Manage Its Debt Responsibly
Aug 21Time To Worry? Analysts Are Downgrading Their Jubilant Pharmova Limited (NSE:JUBLPHARMA) Outlook
Jun 08An Intrinsic Calculation For Jubilant Pharmova Limited (NSE:JUBLPHARMA) Suggests It's 39% Undervalued
May 25Analysts Just Made A Major Revision To Their Jubilant Pharmova Limited (NSE:JUBILANT) Revenue Forecasts
Feb 10Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBILANT)
Feb 08
Shareholder Returns
| JUBLPHARMA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 0.7% | 2.0% | -0.3% |
| 1Y | 91.2% | 39.5% | 16.3% |
Return vs Industry: JUBLPHARMA exceeded the Indian Pharmaceuticals industry which returned 39.1% over the past year.
Return vs Market: JUBLPHARMA exceeded the Indian Market which returned 17.2% over the past year.
Price Volatility
| JUBLPHARMA volatility | |
|---|---|
| JUBLPHARMA Average Weekly Movement | 6.0% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: JUBLPHARMA has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: JUBLPHARMA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 5,399 | Priyavrat Bhartia | www.jubilantpharmova.com |
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others.
Jubilant Pharmova Limited Fundamentals Summary
| JUBLPHARMA fundamental statistics | |
|---|---|
| Market cap | ₹173.23b |
| Earnings (TTM) | ₹5.93b |
| Revenue (TTM) | ₹69.20b |
29.5x
P/E Ratio2.5x
P/S RatioIs JUBLPHARMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JUBLPHARMA income statement (TTM) | |
|---|---|
| Revenue | ₹69.20b |
| Cost of Revenue | ₹23.90b |
| Gross Profit | ₹45.29b |
| Other Expenses | ₹39.36b |
| Earnings | ₹5.93b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 31, 2025
| Earnings per share (EPS) | 37.45 |
| Gross Margin | 65.46% |
| Net Profit Margin | 8.57% |
| Debt/Equity Ratio | 47.7% |
How did JUBLPHARMA perform over the long term?
See historical performance and comparisonDividends
0.5%
Current Dividend Yield103%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 11:24 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jubilant Pharmova Limited is covered by 31 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Harith Ahamed | Avendus Spark |
| Deepak Khetan | Axis Capital Limited |
| Gaurav Chugh | Batlivala & Karani Securities India Pvt. Ltd. |